Last reviewed · How we verify
Coalition for National Trauma Research — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Pathogen-Reduced Plasma | Pathogen-Reduced Plasma | marketed | Blood product / Plasma derivative | Hematology / Transfusion Medicine |
Therapeutic area mix
- Hematology / Transfusion Medicine · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Baxter Healthcare Corporation · 1 shared drug class
- Erasmus Medical Center · 1 shared drug class
- Rigshospitalet, Denmark · 1 shared drug class
- Rutgers, The State University of New Jersey · 1 shared drug class
- Vascular Solutions LLC · 1 shared drug class
- Vastra Gotaland Region · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Coalition for National Trauma Research:
- Coalition for National Trauma Research pipeline updates — RSS
- Coalition for National Trauma Research pipeline updates — Atom
- Coalition for National Trauma Research pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Coalition for National Trauma Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/coalition-for-national-trauma-research. Accessed 2026-05-16.